Citations

Clear

89 citation(s) found for "Lightner, A L".

Editorial: biologic therapies for primary sclerosing cholangitis—more disappointment than promise? Authors’ reply
Tse, Chung Sang , Loftus, Edward V. , Raffals, Laura E. , Gossard, Andrea A., Lightner, Amy L. , Tse, C S , Lightner, A L , Loftus, Edward V

Mayo Clinic

Alimentary Pharmacology & Therapeutics | August 10, 2018 | Volume: 48 | Issue: 5 | Pages: 578-579

10.1111/apt.14907 | PMID 30156321 Get It

Linked ContentThis article is linked to Tse et al and Ma and Kotze paper. To view these articles visit https://doi.org/10.1111/apt.14829 and https://doi.org/10.1111/apt.14858.
Expert Commentary on the Management of Ulcerative Colitis
Lightner, Amy L.

Mayo Clinic

Diseases of the Colon & Rectum | August 7, 2018 | Volume: 61 | Issue: 9 | Pages: 1013-1015

10.1097/dcr.0000000000001174 | PMID 30086049 Get It

‘Watch and wait’ after chemoradiotherapy for rectal cancer
Mullaney, T G, Johnston, Michael , Keck, James, Wattchow, David A. , Mullaney, Tamara G , Lightner, Amy L.

Mayo Clinic

ANZ Journal of Surgery | July 26, 2018 | Volume: 88 | Issue: 9 | Pages: 836-841

10.1111/ans.14352 | PMID 30047201 Get It

Surgery remains the cornerstone of rectal cancer treatment. However, there is significant morbidity and mortality associated with pelvic surgery, and the past decade has illustrated that a cohort of rectal cancer patients sustain a remission of local disease with chemoradiation alone. Thus, questions remain regarding the optimal management for rectal cancer; namely, accurately identifying patients who have a complete pathologic response and determining the oncologic safety of the observational approach for this patient group. This review aims to summarize the current evidence to provide an overview to the ‘watch and wait’ approach in rectal cancer patients with a complete response to neoadjuvant chemoradiation therapy.
Revisional and Reconstructive Surgery for Failing IPAA is Associated with Good Function and Pouch Salvage in Highly Selected Patients
Shogan, Benjamin D. , Mathis, Kellie L. , Duchalais, Émilie , Pembérton, John H., Dozois, Eric J. , Lightner, Amy L. , Larson, David W.

Mayo Clinic

Diseases of the Colon & Rectum | June 26, 2018 | Volume: 61 | Issue: 8 | Pages: 920-930

10.1097/dcr.0000000000001130 | PMID 29944583 Get It

BACKGROUND: Revisional and reconstructive surgery for IPAA is rare given the high success of pouch surgery for chronic ulcerative colitis. Limited data exist on both surgical and functional outcomes in patients with chronic ulcerative colitis who undergo IPAA revision or reconstruction. OBJECTIVE: This study aimed to determine the surgical and functional outcome in patients with chronic ulcerative colitis who undergo IPAA revision or reconstruction. DESIGN: A prospectively collected surgical database was accessed for this study. SETTING: This study was conducted at an IBD referral center. PATIENTS: Patients with chronic ulcerative colitis who underwent IPAA revision or reconstruction were selected. MAIN OUTCOME MEASURES: The primary outcomes measured were 30-day postoperative outcomes and long-term pouch function. RESULTS: Eighty-one patients were identified. Original IPAA was performed for chronic ulcerative colitis (n = 71; 88%) and indeterminate colitis (n = 11; 12.%), and the most common configuration was a J-pouch (n = 69; 86%) with handsewn anastomosis (n = 41;68%). No independent predictors of 30-day postoperative complications following reconstructive/revisional surgery were identified. Pelvic abscesses and Crohn’s disease of the pouch were independently associated with ultimate pouch excision. Median follow-up following revision/reconstruction was 40 months (range, 1–292 months) during which 15 patients (23%) had pouch failure. The 5- and 10-year pouch survival rates following revision were 85 ± 5% and 65 ± 9% by Kaplan-Meier estimation; age <30 years was significantly associated with pouch survival. Long-term function (n = 30; 35%) compared with a matched control cohort of primary IPAA was characterized by significantly increased daytime bowel incontinence (p = 0.0119), liquid stool (p = 0.0062), and medication to thicken stools (p = 0.0452). LIMITATIONS: This was a single-center series, and response rate for functional data was 35%. CONCLUSIONS: In properly selected patients with a failing pouch, originally made for chronic ulcerative colitis or indeterminate colitis, revisional and reconstructive surgery is associated with low complication rates, high pouch salvage, and acceptable long-term pouch function. See Video Abstract at http://links.lww.com/DCR/A640.
Vedolizumab and early postoperative complications in nonintestinal surgery: a case-matched analysis
Kotze, Paulo Gustavo , McKenna, Nicholas P. , Almutairdi, Abdulelah , Kaplan, Gilaad G. , Raffals, Laura E. , Loftus, Edward V. , Mckenna, Nicholas, Loftus, Edward V , Kotze, Paulo G , Kaplan, Gilaad G , Ma, Christopher , Panaccione, Remo , Lightner, Amy L. , McKenna, Nicholas P

Mayo Clinic

Therapeutic Advances in Gastroenterology | June 21, 2018 | Volume: 11 | Issue: No issue available | Pages: No page available

10.1177/1756284818783614 | PMID 29977340 Get It

Background: Vedolizumab (VDZ) is a gut-specific α4-β7 integrin antagonist that has demonstrated efficacy in Crohn’s disease (CD) and ulcerative colitis (UC). The safety of VDZ in the perioperative period remains unclear. The aim of this study was to evaluate postoperative complications and perioperative safety in VDZ-treated patients undergoing nonintestinal operations. Methods: A case-matched study was performed at two inflammatory bowel disease (IBD) referral centers. Adult patients with CD and UC who underwent a nonintestinal surgical procedure during treatment with VDZ were included. Patients who had their last VDZ infusion up to 12 weeks before the procedure were considered exposed and were matched in a 1:1 ratio to patients without VDZ therapy, according to type of surgical procedure, age, and sex. The primary outcome was overall risk of early postoperative infectious complications (up to 30 days after surgery), readmissions, reoperations, surgical site infections, and other infections. The VDZ and control groups were subsequently compared using the Pearson χ2 test and Wilcoxon rank sum. Results: We identified 34 patients treated with VDZ who underwent 36 nonintestinal surgical procedures. These patients were matched with 36 control procedures. Postoperative complications were not different between the VDZ-treated and control cohorts for all outcomes analyzed: infectious complications occurred in 14% versus 8% ( p = 0.45), superficial surgical site infections 6% versus 0% ( p = 0.15), reoperations 6% versus 3% ( p = 0.56) and readmissions 11% versus 6% ( p = 0.37). Conclusions: VDZ-treated patients with IBD undergoing nonintestinal procedures did not have an increased risk of overall postoperative infections or other complications compared with matched controls.
Robotic Platform for an IPAA
Lightner, Amy L. , Kelley, Scott R. , Larson, David W.

Mayo Clinic

Diseases of the Colon & Rectum | June 7, 2018 | Volume: 61 | Issue: 7 | Pages: 869-874

10.1097/dcr.0000000000001125 | PMID 29878953 Get It

INTRODUCTION: An IPAA is the preferred operative approach for restoration of intestinal continuity in patients with ulcerative colitis and familial adenomatous polyposis. As minimally invasive approaches have become more widely adopted, their use in IPAA has also become increasingly commonplace. Laparoscopy has the same limitations during the proctectomy portion as seen in operations for rectal cancer, including dissection in the mid-to-lower rectum attributed to angles created by bony confines of the deep pelvis and lack of visibility when constructing the anastomosis. Robotic surgery provides improved 3-dimensional and high-definition visualization of the pelvis and multiple degrees of freedom, which greatly enhance performance during the proctectomy and construction of the anastomosis. TECHNIQUE: In the setting of a previous subtotal colectomy, the ileostomy site is taken down and stapled across. A 15-mm balloon trocar is placed in the site to achieve insufflation, and the robotic ports are placed horizontally just above the umbilicus. The lateral mesenteric attachments are mobilized laparoscopically, then the J-pouch is constructed through the ostomy site. The J-pouch is placed back into the abdomen with the anvil in place, and the proctectomy is performed after docking the robot. The rectum is stapled with the robotic stapler and exteriorized from the ileostomy site, and the anastomosis is constructed under direct robotic visualization. RESULTS: In addition to the potential ergonomic advantages, the maneuverability and visualization in the pelvis during the proctectomy and construction of the anastomosis are reported by many surgeons to be improved as compared with laparoscopy, especially in male or obese patients. CONCLUSIONS: A robotic approach during the proctectomy and IPAA offers significant advantages to a laparoscopic approach, expanding our armamentarium of minimally invasive surgical techniques to IPAA.
Effects of vedolizumab, adalimumab and infliximab on biliary inflammation in individuals with primary sclerosing cholangitis and inflammatory bowel disease
Tse, Chung Sang , Loftus, Edward V. , Raffals, Laura E. , Gossard, Andrea A., Lightner, Amy L. , Tse, C S , Lightner, A L , Loftus, Edward V

Mayo Clinic

Alimentary Pharmacology & Therapeutics | May 29, 2018 | Volume: 48 | Issue: 2 | Pages: 190-195

10.1111/apt.14829 | PMID 29808485 Get It

SummaryBackgroundPrimary sclerosing cholangitis (PSC) is a chronic, progressive cholestatic biliary disease associated with inflammatory bowel disease (IBD) with no known cure.AimTo evaluate the effect of biological therapies on PSC progression in IBD patients.MethodsWe performed a retrospective cohort study of 88 cases (75 unique patients with 12 patients treated >1 biologics) of IBD (48 ulcerative colitis, 24 Crohn's disease and 3 indeterminate colitis) with concomitant PSC who received biological therapy (42 infliximab, 19 adalimumab, 27 vedolizumab) between June 2002 and October 2017. Hepatic biochemistries were compared using the paired t‐test (patients served as their own controls) ≤3 months before and 6‐8 and 12‐14 months after biological initiation. Radiographic information of biliary stenosis and liver fibrosis were obtained via abdominal ultrasound, abdominal magnetic resonance imaging and magnetic resonance elastography.ResultsUse of adalimumab was associated with a significant decrease in alkaline phosphatase (ALP) after 6‐8 months (P = 0.03; mean change −70 U/L, standard deviation [SD] 88 U/L) compared to vedolizumab (mean change +50 U/L, SD 142 U/L) or infliximab (mean change +37 U/L, SD 183 U/L) but the change was not significant after 12‐14 months (P = 0.24). No significant decreases were observed with AST, ALT, total or direct bilirubin, elastography score or radiographic imaging of biliary tree dilation/strictures with any biological therapy after 6‐8 or 12‐14 months.ConclusionsCurrent evidence suggests that biological therapies used for the treatment of IBD are not effective treatments for PSC. Further study is needed to elucidate any potential beneficial effect of adalimumab on PSC.
J Pouch: Imaging Findings, Surgical Variations, Natural History, and Common Complications
Reber, Joshua D. , Barlow, John M. , Sheedy, Shannon P. , Bruining, David H. , Menias, Christine O. , Fletcher, Joel G. , Fletcher, Joel G , Lightner, Amy L.

Mayo Clinic

RadioGraphics | May 22, 2018 | Volume: 38 | Issue: 4 | Pages: 1073-1088

10.1148/rg.2018170113 | PMID 29787362 Get It

Importance of Considering Portomesenteric Vein Thrombosis and Operation in the Risk of Venous Thromboembolism After Colorectal Surgery
McKenna, Nicholas P. , Lightner, Amy L.

Mayo Clinic

Diseases of the Colon & Rectum | May 17, 2018 | Volume: 61 | Issue: 7 | Pages: e350-e350

10.1097/dcr.0000000000001115 | PMID 29771802 Get It

A Cell-Based Approach to the Treatment of Inflammatory Bowel Disease—Entering an Era of Regenerative Medicine
Lightner, Amy L.

Mayo Clinic

Inflammatory Bowel Diseases | May 17, 2018 | Volume: 24 | Issue: 8 | Pages: 1689-1694

10.1093/ibd/izy084 | PMID 29788100 Get It